BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
Level 5 - mechanism / opinion, no new human data
Narrative literature review summarizing preclinical studies and limited pilot clinical reports
PubMed 42198317 · doi:10.3390/pharmaceutics18050625
What was done
This narrative review searched PubMed/MEDLINE, Embase, Cochrane Library, patent databases, and regulatory agency websites (FDA, EMA, WADA) through April 2026. The authors evaluated literature on BPC-157 focusing on biopharmaceutical properties, pharmacokinetics, formulation challenges, and translational barriers. No formal study quality assessment instrument was applied.
What was found
Preclinical ADME data across two species showed linear dose-proportional kinetics, an intramuscular bioavailability of 14% to 51%, and a plasma half-life under 30 minutes, which was also reported in a preliminary two-subject human pilot. The peptide lacks Biopharmaceutics Classification System (BCS) data, formal permeability testing, excipient compatibility studies, and validated pharmaceutical formulations. Existing clinical data are restricted to fewer than 30 subjects across three uncontrolled pilot studies using non-standardized preparations, with no completed Phase II clinical trials.
Why it matters
This paper highlights that clinical translation of BPC-157 is blocked by an absence of foundational pharmaceutical development and human pharmacokinetics rather than an absence of preclinical biological activity.
Limits
The review is narrative without systematic scoring or quality assessment. Clinical evidence is limited to fewer than 30 total participants in uncontrolled pilot trials, and the paper presents no new experimental data.